Qualification and verification of protein biomarker candidates

Yingxin Zhao, Allan R. Brasier

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

The importance of biomarkers has long been recognized by the public, scientific community, and industry. Yet despite extensive efforts and funding investments in biomarker discovery, only 109 protein biomarkers in plasma or serum were approved by the US Food and Drug Administration throughout 2008 (Anderson NL. Clin Chem 56:177–185, 2010), and even fewer protein biomarkers are currently used routinely in the clinic. In recent years, the introduction of new protein biomarkers approved by the US Food and Drug Administration has fallen to an average of 1.5 per year (a median of only 1 per year) (Anderson NL. Clin Chem 56:177–185, 2010). The low efficiency of biomarker development is due to several reasons, including the poor quality of clinical samples, the gap between subjective clinical definition of a disease and objective protein measurements, and high false discovery rate of differentially expressed proteins identified in the initial discovery phase (Rifai N, Gillette MA, Carr SA. Nat Biotechnol 24:971–983, 2006). It has become clear that the vast majority of differentially expressed proteins identified in the discovery phase will ultimately fail as useful clinical biomarkers, and only few true positive candidates can move through the biomarker development pipeline. Isolation of true biomarkers from the large pool of differentially expressed proteins identified in the discovery phase becomes the greatest challenge and the bottleneck in most biomarker pipelines. To succeed, after the initial discovery study (see Chap. 20), the authenticity of biomarker candidates need to be tested in a pilot study with high throughput, high accuracy and reasonable cost. This essential process is addressed by qualification and verification phase of the biomarker development pipeline.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages493-514
Number of pages22
Volume919
DOIs
StatePublished - 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume919
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Biomarkers
Proteins
Pipelines
United States Food and Drug Administration
Industry
Throughput
Plasmas
Costs and Cost Analysis

Keywords

  • Accurate inclusion mass screening (AIMS)
  • Biomarker verification
  • Cohort selection
  • Data-independent MS/MS acquisition (DIA-MS/MS)
  • ELISA-based verification
  • Parallel reaction monitoring (PRM)
  • Selected reaction monitoring (SRM)

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Zhao, Y., & Brasier, A. R. (2016). Qualification and verification of protein biomarker candidates. In Advances in Experimental Medicine and Biology (Vol. 919, pp. 493-514). (Advances in Experimental Medicine and Biology; Vol. 919). Springer New York LLC. https://doi.org/10.1007/978-3-319-41448-5_23

Qualification and verification of protein biomarker candidates. / Zhao, Yingxin; Brasier, Allan R.

Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. p. 493-514 (Advances in Experimental Medicine and Biology; Vol. 919).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhao, Y & Brasier, AR 2016, Qualification and verification of protein biomarker candidates. in Advances in Experimental Medicine and Biology. vol. 919, Advances in Experimental Medicine and Biology, vol. 919, Springer New York LLC, pp. 493-514. https://doi.org/10.1007/978-3-319-41448-5_23
Zhao Y, Brasier AR. Qualification and verification of protein biomarker candidates. In Advances in Experimental Medicine and Biology. Vol. 919. Springer New York LLC. 2016. p. 493-514. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-41448-5_23
Zhao, Yingxin ; Brasier, Allan R. / Qualification and verification of protein biomarker candidates. Advances in Experimental Medicine and Biology. Vol. 919 Springer New York LLC, 2016. pp. 493-514 (Advances in Experimental Medicine and Biology).
@inbook{201970197b3948a2ad4824fef83ef705,
title = "Qualification and verification of protein biomarker candidates",
abstract = "The importance of biomarkers has long been recognized by the public, scientific community, and industry. Yet despite extensive efforts and funding investments in biomarker discovery, only 109 protein biomarkers in plasma or serum were approved by the US Food and Drug Administration throughout 2008 (Anderson NL. Clin Chem 56:177–185, 2010), and even fewer protein biomarkers are currently used routinely in the clinic. In recent years, the introduction of new protein biomarkers approved by the US Food and Drug Administration has fallen to an average of 1.5 per year (a median of only 1 per year) (Anderson NL. Clin Chem 56:177–185, 2010). The low efficiency of biomarker development is due to several reasons, including the poor quality of clinical samples, the gap between subjective clinical definition of a disease and objective protein measurements, and high false discovery rate of differentially expressed proteins identified in the initial discovery phase (Rifai N, Gillette MA, Carr SA. Nat Biotechnol 24:971–983, 2006). It has become clear that the vast majority of differentially expressed proteins identified in the discovery phase will ultimately fail as useful clinical biomarkers, and only few true positive candidates can move through the biomarker development pipeline. Isolation of true biomarkers from the large pool of differentially expressed proteins identified in the discovery phase becomes the greatest challenge and the bottleneck in most biomarker pipelines. To succeed, after the initial discovery study (see Chap. 20), the authenticity of biomarker candidates need to be tested in a pilot study with high throughput, high accuracy and reasonable cost. This essential process is addressed by qualification and verification phase of the biomarker development pipeline.",
keywords = "Accurate inclusion mass screening (AIMS), Biomarker verification, Cohort selection, Data-independent MS/MS acquisition (DIA-MS/MS), ELISA-based verification, Parallel reaction monitoring (PRM), Selected reaction monitoring (SRM)",
author = "Yingxin Zhao and Brasier, {Allan R.}",
year = "2016",
doi = "10.1007/978-3-319-41448-5_23",
language = "English (US)",
volume = "919",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "493--514",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Qualification and verification of protein biomarker candidates

AU - Zhao, Yingxin

AU - Brasier, Allan R.

PY - 2016

Y1 - 2016

N2 - The importance of biomarkers has long been recognized by the public, scientific community, and industry. Yet despite extensive efforts and funding investments in biomarker discovery, only 109 protein biomarkers in plasma or serum were approved by the US Food and Drug Administration throughout 2008 (Anderson NL. Clin Chem 56:177–185, 2010), and even fewer protein biomarkers are currently used routinely in the clinic. In recent years, the introduction of new protein biomarkers approved by the US Food and Drug Administration has fallen to an average of 1.5 per year (a median of only 1 per year) (Anderson NL. Clin Chem 56:177–185, 2010). The low efficiency of biomarker development is due to several reasons, including the poor quality of clinical samples, the gap between subjective clinical definition of a disease and objective protein measurements, and high false discovery rate of differentially expressed proteins identified in the initial discovery phase (Rifai N, Gillette MA, Carr SA. Nat Biotechnol 24:971–983, 2006). It has become clear that the vast majority of differentially expressed proteins identified in the discovery phase will ultimately fail as useful clinical biomarkers, and only few true positive candidates can move through the biomarker development pipeline. Isolation of true biomarkers from the large pool of differentially expressed proteins identified in the discovery phase becomes the greatest challenge and the bottleneck in most biomarker pipelines. To succeed, after the initial discovery study (see Chap. 20), the authenticity of biomarker candidates need to be tested in a pilot study with high throughput, high accuracy and reasonable cost. This essential process is addressed by qualification and verification phase of the biomarker development pipeline.

AB - The importance of biomarkers has long been recognized by the public, scientific community, and industry. Yet despite extensive efforts and funding investments in biomarker discovery, only 109 protein biomarkers in plasma or serum were approved by the US Food and Drug Administration throughout 2008 (Anderson NL. Clin Chem 56:177–185, 2010), and even fewer protein biomarkers are currently used routinely in the clinic. In recent years, the introduction of new protein biomarkers approved by the US Food and Drug Administration has fallen to an average of 1.5 per year (a median of only 1 per year) (Anderson NL. Clin Chem 56:177–185, 2010). The low efficiency of biomarker development is due to several reasons, including the poor quality of clinical samples, the gap between subjective clinical definition of a disease and objective protein measurements, and high false discovery rate of differentially expressed proteins identified in the initial discovery phase (Rifai N, Gillette MA, Carr SA. Nat Biotechnol 24:971–983, 2006). It has become clear that the vast majority of differentially expressed proteins identified in the discovery phase will ultimately fail as useful clinical biomarkers, and only few true positive candidates can move through the biomarker development pipeline. Isolation of true biomarkers from the large pool of differentially expressed proteins identified in the discovery phase becomes the greatest challenge and the bottleneck in most biomarker pipelines. To succeed, after the initial discovery study (see Chap. 20), the authenticity of biomarker candidates need to be tested in a pilot study with high throughput, high accuracy and reasonable cost. This essential process is addressed by qualification and verification phase of the biomarker development pipeline.

KW - Accurate inclusion mass screening (AIMS)

KW - Biomarker verification

KW - Cohort selection

KW - Data-independent MS/MS acquisition (DIA-MS/MS)

KW - ELISA-based verification

KW - Parallel reaction monitoring (PRM)

KW - Selected reaction monitoring (SRM)

UR - http://www.scopus.com/inward/record.url?scp=85006489182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006489182&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-41448-5_23

DO - 10.1007/978-3-319-41448-5_23

M3 - Chapter

VL - 919

T3 - Advances in Experimental Medicine and Biology

SP - 493

EP - 514

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -